EPS Q/Q společnosti Abeona Therapeutics Inc
Jaká je hodnota metriky EPS Q/Q společnosti Abeona Therapeutics Inc?
Hodnota metriky EPS Q/Q společnosti Abeona Therapeutics Inc je -15.43%
Jaká je definice metriky EPS Q/Q?
Čtvrtletní růst EPS (Quarterly EPS growth rate) ze čtvrtletí na čtvrtletí, je nárůst EPS společnosti za poslední čtyři čtvrtletí v porovnání s výsledky z minulých čtyř čtvrtletí.
The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS Q/Q společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Abeona Therapeutics Inc
Čemu se věnuje společnost Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Firmy s metrikou eps q/q podobnou společnosti Abeona Therapeutics Inc
- Hodnota metriky EPS Q/Q společnosti Metlife Inc je -15.61%
- Hodnota metriky EPS Q/Q společnosti EyePoint Pharmaceuticals Inc je -15.52%
- Hodnota metriky EPS Q/Q společnosti Motus GI Inc je -15.50%
- Hodnota metriky EPS Q/Q společnosti Evoke Pharma Inc je -15.48%
- Hodnota metriky EPS Q/Q společnosti ageas SA/NV je -15.46%
- Hodnota metriky EPS Q/Q společnosti Mohawk Industries je -15.44%
- Hodnota metriky EPS Q/Q společnosti Abeona Therapeutics Inc je -15.43%
- Hodnota metriky EPS Q/Q společnosti Travelers Companies je -15.38%
- Hodnota metriky EPS Q/Q společnosti Marker Therapeutics je -15.38%
- Hodnota metriky EPS Q/Q společnosti Theratechnologies je -15.38%
- Hodnota metriky EPS Q/Q společnosti Niu Technologies je -15.38%
- Hodnota metriky EPS Q/Q společnosti First National (Ontario) je -15.38%
- Hodnota metriky EPS Q/Q společnosti Coupa Software Inc je -15.38%